Keyphrases
Matrix-assisted Laser Desorption Ionization-time of Flight Mass Spectrometry (MALDI-TOF MS)
100%
Ubiquitin
72%
Ubiquitylation
68%
UBE2T
53%
E3 Ligase Activity
45%
Deubiquitinating Enzyme
45%
Parkin
45%
High-throughput
45%
Non-canonical
45%
E3 Ligase
16%
Cellular Processes
16%
Cellular Homeostasis
16%
Parkinson's Disease
15%
In Vitro Activity
15%
Structural Prediction
9%
Enzymatic Cascade
9%
Ubiquitin Modification
9%
Lysine
9%
Post-translational Modification
9%
Threonine
9%
Side Chain
9%
Modeling Tools
9%
Structural Modeling
9%
Prediction Tool
9%
High-throughput Platform
7%
Complementary Matrices
7%
Primary Screening
7%
Cooperative Behavior
7%
Pharmacological Treatment
7%
Treatment Strategy
7%
Conjugation
7%
In Vitro Characterization
7%
Small Molecules
7%
Therapeutic Approaches
7%
Human Genome
7%
Gain-of-function mutation
7%
Patients with Parkinson's Disease
7%
E3 Ubiquitin Ligase
7%
Enzyme Function
7%
Ubiquitin-like
7%
Ubiquitination
7%
Tight
7%
Ligation
7%
Progressive Neurological Disease
7%
Accurate Quantification
7%
Autonomic Abnormalities
7%
E1 Enzyme
7%
Non-motor Symptoms
7%
Biochemistry, Genetics and Molecular Biology
Enzyme
90%
Ubiquitin
81%
Ubiquitination
63%
Time-of-Flight Mass Spectrometry
54%
Matrix-Assisted Laser Desorption/Ionization
54%
Homeostasis
13%
Ubiquitin Ligase
13%
Posttranslational Modification
9%
Lysine
9%
Serine
9%
Threonine
9%
Deubiquitylating Enzyme
9%
Neuroscience
Mass Spectrometry
45%
Parkin
45%
Ligase
45%
Parkinson's Disease
22%
In Vitro
15%
Ubiquitin Protein Ligase E3
7%
Nervous System Disorder
7%
Non-Motor Symptoms
7%
Loss of Function Mutation
7%
Drug Therapy
7%